Industry News
Biotechnology Industry News
Pulmatrix may have been discarded…
Pulmatrix may have been discarded by Cullgen, but the inhaled therapy biotech’s Nasdaq listing has caught the attention of another company.
Oral peptide specialist Pinnacle…
Oral peptide specialist Pinnacle Medicines has secured an $89 million series B with backing from investors in the U.S. and China, bringing the company’s total fundraising haul to $134 million.
John Stanford spent a busy day on…
John Stanford spent a busy day on Capitol Hill this week making the case that the success of the domestic biotech industry is an issue of national security, health care access and economic competitiveness.
Wave Life Sciences linked its…
Wave Life Sciences linked its obesity drug candidate to a 1% dip in body weight after six months, leading investors to drive the stock down by more than 50% despite the biotech hailing the data
Biopharma funding fell 20% last…
Biopharma funding fell 20% last year, reversing the post-pandemic recovery as the IPO haul dropped to the lowest level of the past 10 years, according to an IQVIA analysis.
Innate Pharma has finally called…
Innate Pharma has finally called time on an NK cell engager in phase 1/2 development as part of an ongoing fine-tuning of the French biotech’s pipeline.
Radioligand therapy has…
Radioligand therapy has irrevocably changed oncology, proving we can map biology and strike cancer cells with unprecedented precision. Research suggests that up to 80% of cancers could potentially be addressed by this approach.
Maze Therapeutics has revealed…
Maze Therapeutics has revealed topline phase 2 data for its lead kidney disease candidate that has analysts heralding its “best-in-class potential.” But many investors were racing for the exits Wednesday.
Merck and Terns Pharmaceuticals…
Merck and Terns Pharmaceuticals have agreed to a $6.7 billion all-cash buyout that delivers a prized leukemia asset to the New Jersey Big Pharma.
Sarepta Therapeutics has shared…
Sarepta Therapeutics has shared initial clinical data on two siRNA candidates, delivering an early look at the wisdom of its decision to bet big on Arrowhead Pharmaceuticals’ pipeline.
China’s BrightGene has served up…
China’s BrightGene has served up a slice of early-stage data to remind everyone that it has a horse in the oral obesity race.
Full 12-month data from Ocugen’s…
Full 12-month data from Ocugen’s phase 2 eye disease gene therapy show the therapy significantly reduces the size of lesions, though the treatment’s smaller effect compared to an earlier preliminary analysis sent the biotech’s stock
Shionogi has struck a deal to take…
Shionogi has struck a deal to take full control of its sleep disorder joint venture, agreeing to pay Apnimed $100 million upfront for its partner’s half of the business.
Innovent Biologics’ eye disease…
Innovent Biologics’ eye disease prospect has matched Bayer and Regeneron’s Eylea in a phase 3 study, teeing up filings for Chinese approval of a molecule that could reduce maintenance dose frequency.
Gilead is paying $1.68 billion for…
Gilead is paying $1.68 billion for a T-cell engager company via a front-loaded deal that could also give new meaning to its aimless partner Galapagos.
The voluntary pause comes less…
The voluntary pause comes less than a month after Aardvark paused a phase 3 trial for a related asset due to cardiac concerns.
Despite signing a deal potentially…
Despite signing a deal potentially worth $2.1 billion, Vivtex Therapeutics CEO Thomas von Erlach, Ph.D., refuses to rest on his laurels.
Looking to devise new drug targets…
Looking to devise new drug targets for inflammatory bowel disease, Merck will pay Flagship Pioneering's Quotient Therapeutics $20 million upfront for access to the biotech’s somatic genomics platform.
Apogee Therapeutics has published…
Apogee Therapeutics has published phase 2 eczema data that suggest its anti-IL-13 antibody is a threat to Eli Lilly, Regeneron and Sanofi, prompting analysts to double their peak sales forecast to $5.2 billion.
Sanofi has returned to T-cell…
Sanofi has returned to T-cell engager territory via an agreement to pay $180 million in the near term for a phase 1-stage trispecific antibody from Kali Therapeutics.